Incyte (NASDAQ:INCY) Downgraded by William Blair to "Market Perform"

Incyte (NASDAQ:INCY - Get Free Report) was downgraded by stock analysts at William Blair from an "outperform" rating to a "market perform" rating in a report released on Tuesday, Marketbeat Ratings reports. William Blair also issued estimates for Incyte's Q2 2025 earnings at $1.11 EPS, Q3 2025 earnings at $1.19 EPS, FY2025 earnings at $4.21 EPS and Q3 2026 earnings at $1.30 EPS.

Several other equities analysts have also weighed in on the stock. Cantor Fitzgerald reaffirmed a "neutral" rating on shares of Incyte in a research report on Friday, January 10th. JMP Securities reaffirmed a "market perform" rating on shares of Incyte in a research report on Tuesday, February 11th. Wells Fargo & Company raised their price objective on shares of Incyte from $68.00 to $70.00 and gave the company an "equal weight" rating in a research report on Thursday, December 19th. Royal Bank of Canada cut their price objective on shares of Incyte from $70.00 to $68.00 and set a "sector perform" rating on the stock in a research report on Tuesday, February 11th. Finally, UBS Group initiated coverage on shares of Incyte in a research report on Tuesday, December 17th. They set a "neutral" rating and a $77.00 price objective on the stock. One research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $75.13.

Remove Ads

Incyte Stock Up 2.2 %

Shares of NASDAQ INCY traded up $1.34 during mid-day trading on Tuesday, reaching $61.92. The company had a trading volume of 4,332,207 shares, compared to its average volume of 2,260,600. The stock has a fifty day moving average of $70.61 and a two-hundred day moving average of $70.11. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.94 and a current ratio of 1.97. The company has a market capitalization of $11.98 billion, a price-to-earnings ratio of 229.34, a PEG ratio of 0.41 and a beta of 0.76. Incyte has a 12-month low of $50.35 and a 12-month high of $83.95.

Incyte (NASDAQ:INCY - Get Free Report) last posted its quarterly earnings results on Monday, February 10th. The biopharmaceutical company reported $1.09 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.57 by ($0.48). Incyte had a return on equity of 0.05% and a net margin of 0.77%. As a group, equities research analysts expect that Incyte will post 4.86 EPS for the current year.

Insider Transactions at Incyte

In other news, EVP Sheila A. Denton sold 599 shares of the firm's stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $69.99, for a total value of $41,924.01. Following the sale, the executive vice president now owns 25,848 shares in the company, valued at approximately $1,809,101.52. This trade represents a 2.26 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Barry P. Flannelly sold 19,807 shares of Incyte stock in a transaction on Friday, March 14th. The stock was sold at an average price of $67.69, for a total transaction of $1,340,735.83. Following the sale, the executive vice president now owns 33,567 shares in the company, valued at $2,272,150.23. This represents a 37.11 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 46,827 shares of company stock worth $3,322,618. Insiders own 17.60% of the company's stock.

Institutional Investors Weigh In On Incyte

A number of institutional investors have recently bought and sold shares of INCY. Point72 Asset Management L.P. acquired a new stake in Incyte during the third quarter worth $156,611,000. Norges Bank acquired a new stake in Incyte during the fourth quarter worth $121,890,000. AQR Capital Management LLC boosted its stake in Incyte by 29.7% during the fourth quarter. AQR Capital Management LLC now owns 3,502,813 shares of the biopharmaceutical company's stock worth $241,519,000 after buying an additional 801,090 shares in the last quarter. Jacobs Levy Equity Management Inc. lifted its holdings in shares of Incyte by 861.0% during the fourth quarter. Jacobs Levy Equity Management Inc. now owns 891,659 shares of the biopharmaceutical company's stock valued at $61,587,000 after acquiring an additional 798,877 shares during the period. Finally, Sound Shore Management Inc. CT lifted its holdings in shares of Incyte by 98.4% during the fourth quarter. Sound Shore Management Inc. CT now owns 1,201,089 shares of the biopharmaceutical company's stock valued at $82,959,000 after acquiring an additional 595,741 shares during the period. Institutional investors and hedge funds own 96.97% of the company's stock.

Incyte Company Profile

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.